The relationship between RSV (human respiratory syncytial virus) infections and invasive infections or pneumonia caused by Streptococcus pneumoniae has been observed epidemiologically for several years. Few fundamental data exist to support the epidemiological relationship. This study will investigate the proportion of pneumococcal carriage in RSV-infected infants and noninfected infants (proportion, serotype profile).
Infants aged 6 months to 18 months inclusive
With bronchiolitis during RSV epidemic season (bronchiolitis group) or without evidence of RSV viral infection (healthy group)
No chronic illness
No history of bronchiolitis
Chronic respiratory illness
Medical history of bronchiolitis or newborn asthma
Treatment with immunosuppressants
Patient on AME
The included population will consist of infants aged 6 to 18 months, divided into two groups. On one hand, infants with RSV bronchiolitis (regardless of severity) and on the other hand, RSV-negative infants (consulting for other reasons, such as trauma, jaundice, etc.). The recruitment age is justified by the peak occurrence of invasive pneumococcal infections, which typically occurs around 12 months of age.
Case-control
Prospective
Swab collection
Other interventionNasopharyngeal swab
nasopharyngeal carriage rate of Streptococcus pneumoniae (Sp)
Comparison of nasopharyngeal carriage rates of Streptococcus pneumoniae (Sp) in healthy infants and infants with RSV bronchiolitis.
serotype profile
Comparison of the predominant serotype between the two groups.
serotype profile
Comparison of the distribution of each serotype between the two groups.
proportion of 13-valent and 23-valent vaccine serotypes
the proportion of 13-valent and 23-valent vaccine serotypes among pneumococcal strains between the two groups
proportion of non-vaccine serotypes
proportion of non-vaccine serotypes among all pneumococcal strains between the two groups
Click on the lead sponsor to view all of their trials.
Assistance Publique - Hôpitaux de Paris
Lead sponsor
National Pneumococcal Reference Center
Collaborator
Infectious Diseases Models for Innovative Therapies
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
